These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36570644)

  • 1. Chronological changes of lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer using SpaceOAR® system.
    Taniguchi T; Iinuma K; Nakano M; Kawase M; Takeuchi S; Kato D; Takai M; Nakane K; Ishihara T; Ito M; Kumano T; Matsuo M; Koie T
    Prostate Int; 2022 Dec; 10(4):207-212. PubMed ID: 36570644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Long-term Changes in Lower Urinary Tract Symptoms in Patients With Prostate Cancer Who Underwent Low-dose-rate Prostate Brachytherapy.
    Iinuma K; Nakano M; Kato T; Kato D; Takai M; Maekawa YM; Nakane K; Mizutani K; Tsuchiya T; Ishihara T; Ito M; Matsuo M; Koie T
    Urology; 2020 Aug; 142():213-220. PubMed ID: 32416115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.
    Onishi K; Tanaka N; Miyake M; Nakai Y; Anai S; Torimoto K; Yamaki K; Asakawa I; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    Clin Transl Radiat Oncol; 2019 Jan; 14():51-58. PubMed ID: 30547097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
    Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
    BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
    Patel AK; Houser C; Benoit R; Smith RP; Beriwal S
    Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study.
    Miyake M; Tanaka N; Asakawa I; Yamaki K; Inoue T; Suzuki S; Hori S; Nakai Y; Anai S; Torimoto K; Toritsuka M; Nakagawa H; Tsukamoto S; Fujii T; Ohbayashi C; Hasegawa M; Kasahara M; Fujimoto K
    Contemp Clin Trials Commun; 2020 Sep; 19():100593. PubMed ID: 32637724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
    Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
    Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in patients who underwent robot-assisted radical prostatectomy compared with those who underwent low-dose-rate brachytherapy.
    Nakai Y; Tanaka N; Asakawa I; Hori S; Miyake M; Yamaki K; Anai S; Torimoto K; Inoue T; Hasegawa M; Fujimoto K
    Prostate; 2023 May; 83(7):701-712. PubMed ID: 36879383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer.
    Yu YD; Kang MH; Choi CI; Shin HS; Oh JJ; Park DS
    World J Urol; 2016 Sep; 34(9):1269-74. PubMed ID: 26868648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor.
    Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Nakai Y; Fujii T; Hasegawa M; Fujimoto K
    Brachytherapy; 2018; 17(3):537-543. PubMed ID: 29402711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
    Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
    BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of peripheral zone thickness in men with lower urinary tract symptoms/benign prostatic hyperplasia.
    Kwon JK; Han JH; Choi HC; Kang DH; Lee JY; Kim JH; Oh CK; Choi YD; Cho KS
    BJU Int; 2016 Feb; 117(2):316-22. PubMed ID: 25807886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
    Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
    Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
    Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder.
    Yoo S; Oh S; Kim HS; Choi HS; Park J; Cho SY; Son H; Jeong H; Lee HW; Cho MC
    BJU Int; 2018 Oct; 122(4):667-672. PubMed ID: 29745000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer.
    Blaivas JG; Weiss JP; Jones M
    BJU Int; 2006 Dec; 98(6):1233-7; discussion 1237. PubMed ID: 17125481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
    BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Masumori N; Tsukamoto T; Yanase M; Horita H; Aoki M
    Adv Urol; 2010; 2010():205251. PubMed ID: 20981257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.